Business Wire

Launch of Netupitant-Palonosetron Fixed Combination (Akynzeo®) in the UK by Chugai Pharma UK Ltd.

Del

Chugai Pharmaceutical Co., Ltd. [Head Office: Chuo-ku, Tokyo; Chairman and CEO: Osamu Nagayama] (Chugai) (TOKYO:4519) and a wholly owned subsidiary of Chugai, Chugai Pharma Marketing Ltd. [Head Office: London, the UK; Managing Director: John Halls] (CPM) and Helsinn Group [Head Office: Lugano, Switzerland; CEO: Riccardo Braglia], the Swiss Group focused on building quality cancer care, today announced that Akynzeo®, an oral fixed-dose combination of netupitant (highly-selective NK1 receptor antagonist) and palonosetron (clinically and pharmacologically distinct 5-HT3 receptor antagonist) indicated for the prevention of chemotherapy-induced nausea and vomiting (CINV), has been launched by a wholly owned subsidiary of CPM, Chugai Pharma UK Ltd. [Head Office: London, the UK; Managing Director: Ruth Currie] (CPU), in the UK as from September 1, 2015. CPM has been granted the exclusive right of Akynzeo for sales and marketing from Helsinn Healthcare S.A.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20150909006849/en/

“Following the launch of Aloxi® starting January this year, we are pleased to deliver a novel new product for the treatment of CINV to patients by CPU.” said John Halls, Managing Director of CPM. “With strong collaboration and partnership with our license partners, including Helsinn, we are confident that CPM will improve our presence in the oncology supportive care in the European market.”

“Helsinn has a great relationship with Chugai and we are delighted that they are our partner in the launch of Akynzeo in the UK.” said Riccardo Braglia, CEO of Helsinn Group. “We believe that Akynzeo can play a significant role in preventing nausea and vomiting in both the acute and delayed phases following chemotherapy treatment, which could lead to more treatment options for the patient.”

CINV is one of the most common side effects of cancer chemotherapy. The prevention of CINV has been refined in treatment guidelines over the past several decades. Currently the combination treatment of antiemetic medicines with different mechanisms of actions are recommended for the prevention of CINV.

Akynzeo provides a combination of two antiemetics in a single oral capsule. A scheme of an NK1 receptor antagonist, a 5-HT3 receptor antagonist and dexamethasone meets the guidelines’ recommendation for optimal antiemetic therapy following highly emetogenic and anthracycline cyclophosphamide based chemotherapy.

As stated in the CHMP Summary of opinion*, the “simplification of therapy by decreasing the number of individual dose units to be taken by the patient may furthermore improve patient compliance.”

Chugai and CPM strongly believe that Akynzeo as a novel new treatment option will deliver great contribution to patients in the UK suffering from CINV.

*http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion/human/003728/WC500184907.pdf

 
Product name:   Akynzeo®
Generic name: Netupitant-Palonosetron
Formulation: Capsule containing Netupitant 300mg / Palonosetron 0.5mg
Indication: - Prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin-based cancer chemotherapy
- Prevention of acute and delayed nausea and vomiting associated with moderately emetogenic cancer chemotherapy
Dosage: Adults
One 300 mg / 0.5 mg capsule should be administered approximately one hour prior to the start of each chemotherapy cycle
EMA approval: May 27, 2015
Marketing authorization holder: Helsinn Healthcare S.A.
Sales and marketing responsibility: Chugai Pharma UK Ltd.
Territor: the UK, Republic of Ireland
Launch date: September 1, 2015 (the UK) / to be confirmed (Ireland)
 

About Chugai Pharma Marketing

Chugai Pharma Marketing Ltd. is the headquarters of all Chugai’s clinical development, regulatory affairs, medical affairs, import, sales and marketing of pharmaceutical products in Europe and coordinates the European marketing operations through subsidiaries located in the UK, France, and Germany. Products which are currently marketed in those countries include “RoActemra® (tocilizumab)”, a humanized anti-human IL-6 receptor monoclonal antibody, “Granocyte® (lenograstim)”, a G-CSF preparation, “Antepsin® (sucralfate)”, an antiulcer agent (marketed in the UK and Ireland), and Aloxi (palonosetron), an antiemetic agent (marketed in the UK). Furthermore, CPM is conducting the clinical development of SA237, anti-IL-6 receptor humanized monoclonal antibody for the treatment of neuromyelitis optica, and CIM331, anti-IL-31 receptor humanized monoclonal antibody for the treatment of Atopic dermatitis.

About Chugai

Chugai Pharmaceutical is one of Japan’s leading research-based pharmaceutical companies with strengths in biotechnology products. Chugai, based in Tokyo, specializes in prescription pharmaceuticals and is listed on the 1st section of the Tokyo Stock Exchange. As an important member of the Roche Group, Chugai is actively involved in R&D activities in Japan and abroad. Specifically, Chugai is working to develop innovative products which may satisfy the unmet medical needs, mainly focusing on the oncology area.
In Japan, Chugai’s research facilities in Gotemba and Kamakura are collaborating to develop new pharmaceuticals and laboratories in Ukima are conducting research for technology development for industrial production. Overseas, Chugai Pharmabody Research based in Singapore is engaged in research focusing on the generation of novel antibody drugs by utilizing Chugai’s proprietary innovative antibody engineering technologies. Chugai Pharma USA and Chugai Pharma Marketing are engaged in clinical development activities in the United States and Europe.
The consolidated revenue in 2014 of Chugai totaled 461.1 billion yen and the operating income was 77.3 billion yen (IFRS Core basis).
Additional information is available on the internet at http://www.chugai-pharm.co.jp/english

About the Helsinn Group

Helsinn is a family run, privately owned pharmaceutical group focused on building quality cancer care with a large portfolio of products. Founded in 1976 with headquarters in Lugano, Switzerland, Helsinn also has operating subsidiaries in Ireland, the United States and a representative office in China. Helsinn's business model is focused on the licensing of pharmaceuticals, medical devices and nutritional supplement products in the therapeutic area of cancer care.
Helsinn Group in‐licenses early‐to‐late stage new chemical entities, completing their development by performing preclinical and clinical studies and associated manufacturing activities. Helsinn then prepares necessary regulatory filings in order to achieve marketing approvals worldwide. Helsinn's products are out‐licensed to its global network of marketing and commercial partners that have been selected for their local market knowledge and high ethical standards. Helsinn supports these partners by providing a full range of product and scientific management services, including commercial, regulatory, and medical marketing advice. In March 2013, Helsinn established a new commercial organization within its subsidiary, Helsinn Therapeutics (U.S.), Inc., in order to conduct direct sales and marketing activities within the U.S. market. Helsinn’s products are manufactured according to the highest quality, safety, and environmental standards at Helsinn's GMP facilities in Switzerland and Ireland from where they are then supplied worldwide to customers.
Further information on Helsinn Group is available at www.helsinn.com.

Contact information

For Media
Chugai Pharmaceutical Co., Ltd
Media Relations Group, Corporate Communications Dept.,
Koki Harada
Tel: +81-3-3273-0881
E-mail: pr@chugai-pharm.co.jp
***
For European media
Chugai Pharma France SAS
Nathalie Leroy
Tel: +33-1-56-37-05-21
***
For Investors
Chugai Pharmaceutical Co., Ltd
Investor Relations Group, Corporate Communications Dept.,
Toshiya Sasai
Tel: +81-3-3273-0554
E-mail: ir@chugai-pharm.co.jp
***
Helsinn Group
Paola Bonvicini
Head of Communication & Press Office
PH +41 91-985-21-21
info-hhc@helsinn.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Düsseldorf Airport to Deploy Next Generation ECAC Standard 3 EDS Screening Technology from Smiths Detection24.1.2018 09:00Pressemelding

Smiths Detection is supplying next generation hold baggage scanners to support the upgrade to ECAC Standard 3 explosives detection systems (EDS) at Düsseldorf Airport. Awarded by the Procurement Office of the German Ministry of Interior, the contract includes 14 advanced HI-SCAN 10080 XCT scanners, which deliver exceptional levels of security; and can be further updated as necessary in the future to detect new explosive threats. There is also an associated eight year service agreement. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180124005070/en/ Düsseldorf Airport to deploy next generation ECAC Standard 3 EDS screening technology from Smiths Detection (Photo: Business Wire) “European airports are currently very focused on upgrading to ECAC Standard 3 approved EDS to meet the new regulations,” commented Tony Tielen VP EMEA, Smiths Detection. “This does, of course, require a financial investment which must be clearly weighed

GleSYS Tap Into Telia Carrier Backbone to Increase Capacity and Support Growth Plans24.1.2018 09:00Pressemelding

Telia Carrier announced today that it is working with one of Sweden’s fastest growing hosting companies, GleSYS , to provide improved capacity and support future growth plans. GleSYS will be connecting to the Telia Carrier global backbone, one of the largest in the world, and the first to be 100G enabled in Europe and North America. GleSYS provides hosting and data centre services to over 4,000 customers in 70 countries. With two fully redundant datacentres in Sweden and a network of cloud hosting locations, GleSYS supports a range of industries, such as eCommerce, where performance, responsiveness and reliability on a global scale have a direct impact on revenues and are therefore critical. Telia Carrier will be providing 100G IP Transport and wavelength network transport services to double available capacity on GleSYS’ current infrastructure, which provides cloud hosting, dedicated servers and colocation in multiple sites across Europe. Eric Lindsjö, Head of Networks at GleSYS, said;

GSMA Announces Nominees for 2018 GLOMO Awards24.1.2018 09:00Pressemelding

The GSMA today announced the nominees for the Global Mobile Awards 2018 (GLOMO Awards). Winners of the awards will be presented throughout Mobile World Congress, which takes place 26 February – 1 March in Barcelona. The full list of nominees can be found at http://gsma.at/glomoshortlist. "The GLOMOs offer organisations and individuals from across the world an opportunity to showcase how mobile technology continues to inspire new levels of ingenuity, innovation and achievement,” said Michael O’Hara, Chief Marketing Officer, GSMA. “As always, the calibre of entries is extremely high, so to be shortlisted for the GLOMOs today is quite an achievement in itself. We wish the very best of luck to all nominees and look forward to unveiling the winners at Mobile World Congress next month.” The GLOMO Awards feature an afternoon ceremony at 15:30 CET on Tuesday, 27 February in Auditorium 5, Hall 4, and will include the presentation of winners in three categories including “Social Good”, “Governme

Integral Expands Cryptocurrency Market Data Services to Include 14 Cryptocurrencies and 16 Exchanges23.1.2018 22:00Pressemelding

Integral (www.integral.com), the financial technology partner trusted by leading banks, brokers, and investment managers to design, deliver and grow their FX businesses, announced today that it has expanded its market data offering for cryptocurrencies to include 14 major cryptocurrencies connecting to all major exchange sources across the U.S., Europe and Asia including Japan and Hong Kong. “An accurate, stable, and reliable reference price is a requirement for any market maker,” said Harpal Sandhu, CEO of Integral. “The Cryptocurrency Market Data Service connects to the most price sources and applies the most advanced price discovery algorithm available.” Integral has years of experience as a technology leader and innovator in foreign exchange and is now applying this ingenuity to the cryptocurrency market. The Market Data Service uses algorithms developed with Stanford University for Integral FX Benchmark to provide the most precise reference prices for cryptocurrencies. “Integral’s

Kimbal Riley to Become Vista Group CEO23.1.2018 21:57Pressemelding

Vista Group International (NZX & ASX: VGL) has today announced that Kimbal Riley will take over as Group CEO from Murray Holdaway. Mr Holdaway will take up the position of Chief Product Officer (CPO) for Vista Group, and will continue in his role as an Executive Director on the Vista Group board. This has taken place as part of a succession planning process and will deliver a seamless transition within the business. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180123006545/en/ Kimbal Riley becomes CEO of Vista Group International (Photo: Business Wire) Mr Riley has had an extensive career in senior executive roles in the IT and Services industries in New Zealand and overseas. He joined Vista Group four years ago, with the past two years as CEO of Vista Entertainment Solutions (VES), which is responsible for the largest proportion of the Group’s revenue. He has been focused on building scale in the business and under his lea

IFF Breaks Ground on Flavors/Fragrances Site in Sri City, India23.1.2018 17:00Pressemelding

Regulatory News: International Flavors & Fragrances Inc. (NYSE: IFF) (Euronext Paris: IFF), a leading innovator of sensory experiences that move the world, has broken ground on a new flavors and fragrances plant located in Sri City, in the State of Andhra Pradesh in India. Part of a larger investment into the Greater Asia region, the plant is expected to be commercialized in December 2019. The new facility, which will be the largest flavor and fragrance manufacturing facility in India and the largest IFF site in Greater Asia, occupies a 32-acre/130,000m2 plot and will serve IFF flavors and fragrances customers across India and the region. “In this economically vibrant country, it is critical that we invest to provide our customers with winning tastes and scents,” said IFF Chairman and CEO Andreas Fibig. “This new facility is fitted with capabilities tailored for our customers’ needs. Coupled with our excellent consumer insights teams and their deep understanding of the local markets, w

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom